Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
Deborah Elstein, Ari ZimranGaucher Clinic, Shaare Zedek Medical Center, Jerusalem, IsraelAbstract: Most patients who suffer from symptomatic Gaucher disease will benefit from enzyme replacement therapy (ERT) with imiglucerase. The safety profile is excellent, only a small percentage of those exposed...
Guardado en:
Autores principales: | Deborah Elstein, Ari Zimran |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/93035db7d71c4af793571bee8f3201da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tres casos de enfermedad de Gaucher tipo I
por: Aída Lemes, et al.
Publicado: (2006) -
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fernando C Fervenza, et al.
Publicado: (2008) -
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project
por: Kylie Thaler, et al.
Publicado: (2009) -
Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch D, et al.
Publicado: (2014) -
Long-read single molecule real-time (SMRT) sequencing of GBA1 locus in Gaucher disease national cohort from Argentina reveals high frequency of complex allele underlying severe skeletal phenotypes: Collaborative study from the Argentine Group for Diagnosis and Treatment of Gaucher Disease
por: G. Drelichman, et al.
Publicado: (2021)